Background {#Sec1}
==========

Neuroblastoma (NB) is the most common extracranial malignant pediatric tumor that typically arises in the adrenal medulla or paraspinal sympathetic ganglia \[[@CR1]\]. The histological differentiation state of NB is highly variable, including undifferentiated "small blue round cell" neoplasms, partial differentiated ganglioneuroblastomas (GNB), and differentiated ganglioneuroma (GN), which consists of clusters of mature neurons surrounded by a dense stroma of Schwann cells. As an immature tumor, NB is aggressive, predominantly occurring in early childhood at a median age of 22 months and accounting for 15% of childhood cancer-related mortality. The overall survival rate for high-risk metastatic disease is 40% \[[@CR2]--[@CR5]\]. Conversely, mature variants (GNB or GN) occur in older children and tend to behave in a more benign fashion \[[@CR6]\].

In addition to tumor histology, many molecular genetic markers of NB have been identified, including amplification of the N-myc proto-oncogene protein (MYCN), mutations of the anaplastic lymphoma kinase (ALK) receptor, allelic deletions in the 1p, 3p and 11q chromosomal regions, chromosomal gain of 17 or tumor cell ploidy \[[@CR7], [@CR8]\]. Amplification of the MYCN gene is associated with poor prognosis and was found in about 20% of NB cases \[[@CR9], [@CR10]\]. ALK is altered by gain-of-function point mutations in around 14% of high-risk NB and confers poorer prognosis for tumors in the intermediate- and high-risk categories \[[@CR11], [@CR12]\].

Treatment regimens for patients with NB differ accordingly and depend on tumor behavior as predicted by tumor histology and molecular features \[[@CR13]\]. Children with low-risk NB can be observed or treated surgically while those with intermediate risk disease may receive chemotherapy prior to surgical resection. Patients with high-risk NB undergo intensive multimodal therapy including chemotherapy, surgical treatment, stem cell transplantation, radiation, and immunotherapy \[[@CR14], [@CR15]\].

Over the past decades, national and international collaborative research efforts have led to increased knowledge of biological and clinical tumor features, thereby refining patient's risk stratification and treatment strategies, leading to significant increases in survival rates. Currently, patients with low- and intermediate-risk NB have an overall survival rate of about 90% \[[@CR16], [@CR17]\]. However, children with high-risk NB still have a poor prognosis \[[@CR3]\]. Even if NB was successfully treated, disease burden persists, as the NB survivors have long-term health consequences due to damage of the organ systems by chemotherapy and radiation therapy. Nearly two thirds of NB survivors have at least one chronic health condition and one third have severe to life-threatening illness \[[@CR18], [@CR19]\]. To improve understanding of the genetic basis of NB, the neuroblastoma research community has collected large numbers of tumor and germline samples. With this, key somatic and germline genomic alterations have been discovered. These collective advancements have led to the development of new therapeutic approaches for high-risk NB \[[@CR20]\].

Given the enormous volume, heterogeneity and variable quality of NB-related publications, an assessment of the scientific literature on this topic is essential for both clinicians and researchers. Hence, we employed scientometric methodologies and innovative visualization tools to analyze extensive bibliographic metadata related to NB research.

The study objectives are: 1) to assess the publication output as proxy for productivity of a researcher (quantity indicator); 2) to gauge the impact of the research on the scientific community by analysis of citation dynamics in NB research during 1980--2018 (quality indicator); 3) to identify and characterize the most prolific authors; 4) to examine the academic journals publishing papers related to NB; 5) to examine geographical distribution of the research performance on NB; 6) to analyze the co-authorship network architecture; 7) to identify the most cited NB papers; 8) to perform a keyword analysis.

Methods {#Sec2}
=======

All peer-reviewed scientific publications relating to NB research were retrieved from the Web of Science™ Core Collection Database (Clarivate Analysis, Boston, USA). The search terms {"neuroblastoma(s)"} OR {"ganglioneuroblastoma(s)"} OR {"ganglioneuroma(s)"} OR {"peripheral neuroblastic tumor(s)"} were used in the title field and results were filtered by publication year from 1980 through 2018. No language restrictions were imposed. The complete metadata for each original publication and review article was compiled and manually exported on November 12, 2019. The "citation report" function from Web of Science was applied to assess citation rates and *h*-index.

Bibliometrix (version 1.7), an R-Tool of R-Studio (Version 3.6.1) for comprehensive science mapping analysis, and biblioshiny, the shiny interface providing a web-interface for bibliometrix, were used to import and manage the metadata from Web of Science™ \[[@CR21]\]. Baseline metadata included print features, such as author's name, corresponding author's country (CAC), total number of publications, citations count with total citations (TC), average article citations (AAC), number of citing articles with and without self-citations, journal sources, keywords, countries/regions, and the author-level metrics such as *h*-, *m*-, and *g* indices. The *h*-index, a common proxy measure for individual scientific output, is defined as the number of papers with citation number ≥ *h* (at least one citation) \[[@CR22]\]. Consequently, the *h*-index depends on both the number of a scientist's publications and their impact on peers (number of citations). Since the *h* -index does not account for the career span of the author, the *m*-index or *m*-quotient (equal to the *h*-index divided by the number of years since the author's first publication \[m-quotient = *h*-index/n, *n* = number of years since the first published paper of the scientist\]) was applied. Further, to account for the citation evolution of the most cited papers of the given author over time, the *g*-index, which gives credit for the most highly cited papers in a data set, was used. The annual growth rate of scientific publications was assessed applying a calculator available at [www.investopedia.com/calculator/cagr.aspx](http://www.investopedia.com/calculator/cagr.aspx).

Collaboration measures included the number of documents per author (documents/author), number of authors per document (authors/document), and number of co-authors per document (author's appearance/documents).

In addition, using the word co-occurrence in our bibliographic data collection, we mapped the conceptual structure of an entire word's framework with a dimensionality reduction technique and Multiple Correspondence Analysis (MCA) \[[@CR23]\] We identified clusters of documents which express common concepts. Words appearing together in an article were related in a network.

VOSviewer (version 1.6.13, <http://www.vosvi>[ewer.com](http://ewer.com)), a network analysis software tool, was used to construct a keyword co-occurrence network \[[@CR24]\]. The co-occurrence of two keywords reflects the number of publications in which both keywords occur together. The size of the circles in the VOSviewer diagram indicates the number of publications that have the corresponding keywords. The link strength between the circles reflects the frequency of keyword's co-occurrence. The total link strength is the sum of link strengths of the keyword over all the other keywords.

CiteSpace IV (Drexel University, Philadelphia, PA, USA, Version 0.65) was applied to determine the keywords with strong citation bursts, which serves as an indicator of the most active area of research attracting a special degree of attention from the scientific community. Relationships between author's keywords, references used, and the top authors were summarized by a Sankey plot (three-fields plot).

Categorical variables were expressed as frequency and percentage, continuous variables were represented as medians with maximum and minimum or as means with standard deviation. The Spearman correlation coefficient was used to test correlations between selected continuous variables. Statistical analyses were performed with SPSS v. 23 (SPSS 23.0 -- SPSS Inc., Chicago Illinosis) and GraphPad Prism v. 6.01 (GraphPad, La Jolla, CA). All tests were two-sided. *P*-values of \< 0.05 were considered statistically significant. This study did not require approval of an ethics committee.

Results {#Sec3}
=======

Overall publication performance and growth rate {#Sec4}
-----------------------------------------------

We first assessed the overall publication performance in NB research during the last 38 years. In total, 12,435 documents, including 11,970 (96.2%) articles and 465 (9.8%) reviews, were published by 36,908 authors from 86 countries. The total publications output was very low prior to 1990 (*n* = 626, 5.0%) and began to increase extensively after 1991, reaching a peak in 2015 (*n* = 572, 4.6%). Linear fitting of the data revealed an increase in the number of publications written between 1980 and 2018 (r^2^ = 0.92 \[CI: 0.86 to 0.96\]; *p* \< 0.0001\]). The average annual percentage growth rate indicating increasing annual scientific production was 11.8%. The highest annual growth rates were noted in 1986 (711%) and in 1990 (519.5%) while the lowest was recorded in 1998 (− 91.1%). After 1991, the growth rates were stable, ranging from − 20.3 to + 31.5% (Fig. [1](#Fig1){ref-type="fig"}, Table [S1](#MOESM6){ref-type="media"}). Fig. 1Overall publication performance in neuroblastoma research from 1980 to 2018, presented as a total number of publications per year, the corresponding annual growth rate, the average citations they received, and the associated *h*-index

Citation rate and dynamics {#Sec5}
--------------------------

Of 12,136 retrieved documents, a total of 316,017 received citations including self-citations and 289,357 were without self-citations. The average citation per item (CPI) was 28.35 ± 7.7. There was a consistent citation dynamic ranging from 29.5 CPI in 1980 to 30.8 CPI in 2010. After 2011, the CPI was 12.7, which was lower compared to the period 1980--2010, because most newly published articles had not been cited much at the time of data extraction for our study. While the number of single-authored documents remains stable over time (r^2^ = − 0.6, *p* = 0.24), the number of multi-authored documents increased significantly (r^2^ = 1.0, *p* = 0.003) (Fig. [2](#Fig2){ref-type="fig"}, Table [S2](#MOESM7){ref-type="media"}). Fig. 2Detailed profile of citation rate and dynamics on neuroblastoma during the last 38 years

Most prolific authors {#Sec6}
---------------------

In the entire dataset of 36,908 authors, 25,873 authors (70.1%) published a single paper related to neuroblastoma and were considered "occasional" authors; 5178 (14.0%) published two papers; 2076 (5.6%) published three papers; 3781 (10.2%) published four or more papers. Authors who published more than one paper were considered to be "core" authors. Of the top ten contributing authors, Berthold F (University of Cologne, Department of Pediatric Oncology and Hematology, University of Cologne, Koeln, Germany) was ranked first in the number of published articles (*n* = 169), Matthay KK (Department of Pediatrics and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA) had the highest *h*- and *m*-indices (63 and 2.2, respectively) while Seeger RC (Division of Hematology/Oncology, Children's Hospital Los Angeles, Los Angeles, USA) had the highest average citation per item count (100.2) (Table [1](#Tab1){ref-type="table"}). Scientific productivity of the top authors on NB research over time is presented in Figure [S1](#MOESM1){ref-type="media"}. Table 1Top 10 contributing authors in field of neuroblastoma researchRankAuthorNumber of publicationsH indexG IndexM IndexArticles FractionalizedAverage citation per itemSum of time cited ( without self citation)PY start1Berthold F16945801.327.643.47420(6838)19862Matthay KK165631132.221.481.013,373(12,305)19923Cheung NKV16050761.433.442.536975(61645)19864Maris JM158561102.219.079.812,661(11,878)19955Cohn SL15654961.620.464.210,016(9434)19876Nakagawara A11833670.917.840.94954(4685)19867Seeger RC116571081.6--100.211,725(11,368)19868Speleman F11639721.5--48.45614(5132)19949Tonini GP11627540.818.429.33429(3163)198710Hero B11239681.5--44.75014(4673)1995Affiliation of the highly cited authorsBerthold F: University of Cologne, Department of Pediatric Oncology and Hematology, University of Cologne, Koeln, GermanyMatthay KK: Department of Pediatrics and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USACheung NKV: Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USAMaris JM: The Children's Hospital of Philadelphia, Division of Oncology, Philadelphia, USACohn SL: Section of Hematology/Oncology, Department of Pediatrics, University of Chicago, ChicagoNakagawara A: Saga Medical Center Koseikan, Saga, JapanSeeger RC: Division of Hematology/Oncology, Children's Hospital Los Angeles, Los Angeles, USASpeleman F: Center for Medical Genetics Ghent, Medical Research Building 1, Ghent, BelgiumTonini GP: Neuroblastoma Laboratory, Italian Neuroblastoma Foundation, Pediatric Research Institute, Fondazione Città della Speranza, Padua, ItalyHero B: University of Cologne, Department of Pediatric Oncology and Hematology, University of Cologne, Koeln, Germany

Core journals {#Sec7}
-------------

In the time frame analyzed, there were 1828 academic journals publishing papers related to neuroblastoma research. *Journal of Neurochemistry* had the highest publication output (*n* = 319, 17.4%), followed by *Cancer Research* (*n* = 295, 16.1%), *Journal of Pediatric Surgery* (*n* = 278, 15.2%), and *Pediatric Blood and Cancer* (*n* = 261, 14.3%). The most cited journals were *Cancer Research* (*n* = 19,170), *Journal of Clinical Oncology* (*n* = 16,426), *Journal of Neurochemistry* (*n* = 10,221), *Oncogene* (*n* = 9223), and *Journal of Biological Chemistry* (*n* = 9197). *Cancer Research* (80) had the highest *h* index, following by *Journal of Clinical Oncology* (75), and *Journal of Biological Chemistry* (56). Table [2](#Tab2){ref-type="table"} summarized source impact of the top 20 journals publishing on NB. Table 2Source impact of the top journals publishing on neuroblastomaSourceIFNPTC***h***-index***g***-index***m***-indexJournal of Neurochemistry4.8731910,22153711.39Cancer Research9.1329519,170801172.35Journal of Pediatric Surgery2.09278440933450.86Pediatric Blood and Cancer2.64261336827401.68Oncogene6.85194922355821.83PLOS One2.77193352827432.07Neuroscience Letters2.15192356831450.86Journal of Clinical Oncology26.318016,426751212.20European Journal of Cancer7.19178522940571.37International Journal of Cancer7.3172512335741.22Cancer Letters6.5171406635481.12Clinical Cancer Research10.2168722849701.96Biochemical and Biophysical Research Communications2.7161351732480.78Cancer6.1153693546761.15Journal of Biological Chemistry4.1151919756871.4Journal of Pediatric Hematology Oncology0.9146189025380.96Brain Research2.9137339030480.83Oncotarget5.1137174023302.3British Journal of Cancer5.9117368435520.89

Active countries {#Sec8}
----------------

Eighty-six countries were involved in NB total research output. Among them, 9999 (80.4%) of publications were contributed by the top twelve most productive countries, putting out more than 300 publications (Table [3](#Tab3){ref-type="table"}). The United States of America (USA) published the most papers (*n* = 4328), had the highest *h*-index (141), and ranked first in terms of single country publications (*n* = 2284). Other high prolific countries were Japan (*n* = 1364), Italy (*n* = 1336), and Germany (*n* = 1128). The Netherlands had the highest rate of average article citations (*n* = 39.12), followed by the USA (*n* = 35.45), France (*n* = 33.24), Sweden (*n* = 33.16), and China (*n* = 32.61). Table 3Most productive countries contributing to neuroblastoma researchRegionTP***h***-indexTCAACUSA4328141113,52535.45Japan13647623,26824.66Italy13367826,13427.85Germany11288521,59731.19UK9107518,42426.78China82944914432.61France7487014,84633.24Sweden4545610,14933.16Spain45455761030.00Canada42752746827.21Netherlands3375413,18439.12South Korea33034526915.97*TP* total production, *TC* total citations, *AAC* average article citations

International collaborations {#Sec9}
----------------------------

Researchers from the USA showed the highest collaboration performance with a total link strength (TLS) of 1438, followed by Germany (TLS = 852), the United Kingdom (TLS = 829), Italy (TLS = 801), and France (TLS = 707). International collaboration analysis showed that 136 articles (30.0%) produced by Sweden had international authors, followed by authors from the UK (*n* = 221, 24.3%), France (*n* = 167, 22.3%), Germany (*n* = 244, 21.6%), and the USA (*n* = 918, 21.2%). The international collaboration network is presented in Figure [S2](#MOESM2){ref-type="media"}. The number of links between any two countries represents the strength of collaboration, while the color intensity is proportional to the number of publications. The strongest collaboration was between the USA and Germany (frequency, *n* = 160), the USA and Italy (*n* = 156), the USA and the UK (*n* = 137), and the UK and Italy (*n* = 131).

Most cited NB papers and NB papers without a single citation {#Sec10}
------------------------------------------------------------

Of 12,435 publications related to NB, 12,136 (94.8%) were cited at least one time and 299 (2.4%) publications remain uncited after their publication. Table [4](#Tab4){ref-type="table"} demonstrates the top ten studies according to total number of citations. The review article entitled "Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment" published by Broder GM in *Journal of Clinical Oncology* in 1993 received the highest number of citations (*n* = 1450). Table 4Most cited neuroblastoma papersAuthors^**a**^ArticleJournalYearVolIssuePageTCTC per yearBroder GM, Pritchard J, Berthold F, Hedborg FRevisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.J Clin Oncol19931181466--77145055.7Kaghad M,Bonnet H, Yang A, Caput DMonoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancersCell1997904809--19140363.7Broder GMNeuroblastoma: Biological insights into a clinical enigmaNat Rec Cancer200333203--16132883.0Matthay KK, Villablanca JG, Seeger RC, ReynoldsTreatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acidN Engl J Med1999341161165--73124662.3Maris JM, Hogarty MD, Bagatell R, Cohn SLNeuroblastomaLancet201036995792106--20115396.1Maris JMRecent Advances in NeuroblastomaN Engl J Med2010362232202--1179288.0Yu AL, Gilman AL, Ozkaynak MF, Sondel PMAnti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for NeuroblastomaN Engl J Med2010363141324--3470778.5Mosse YP, Laudenslager M, Longo L, Maris JMIdentification of ALK as a major familial neuroblastoma predisposition geneNature20084557215930--570464.0Shimada H, Chatten J, Newton WA, Misugi KHistopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomasJ Natl Cancer Inst1984732405--1668619.6Pule M, Savoldo B, Myers GD, Brenner MKVirus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaNat Med200814111264--7067461.3^**a**^ first, second, third, and last authors

Keywords analysis {#Sec11}
-----------------

The most frequent author's keywords were "neuroblastoma" (*n* = 4505), "apoptosis" (*n* = 821), "differentiation" (*n* = 371), "mycn" (*n* = 262), "ganglioneuroma" (*n* = 222), "oxidative stress" (*n* = 218), "neuroblastoma cells" (*n* = 214), "retinoic acid" (*n* = 195), "chemotherapy" (*n* = 153), "SH-SY5Y" (*n* = 153). The overall keyword network visualization is presented in Fig. [3](#Fig3){ref-type="fig"}. We identified keywords with a high-citation burst, which can be used to predict research areas attracting an extraordinary degree of attention (Figure [S3](#MOESM3){ref-type="media"}). Next, we aimed to map the conceptual co-word structure using the word co-occurrences in our bibliographic metadata to identify clusters of documents which express common concepts. The results are plotted on a two-dimensional map (Figure [S4](#MOESM4){ref-type="media"}). Overall, 7 clusters of words could be identified (each color represents a cluster of word). The three-fields plot shows the relationship between the author's keywords (research contents = right field), references authors use (intelectual roots = left field), and the top authors (middle field) (Figure [S5](#MOESM5){ref-type="media"}). Fig. 3The keywords co-occurrence network. Minimum number of occurrence of a keyword = 10, minimum links strength = 10. Overall, 1638 keywords met threshold criteria. There are 7 clusters of keywords: red indicates Cluster 1 (*n* = 449), green indicates Cluster 2 (*n* = 341), blue indicates Cluster 3 (*n* = 285), yellow indicates Cluster 4 (*n* = 246), purple indicates Cluster 5 (*n* = 214), light-blue indicates Cluster 6 (*n* = 94), orange indicates Cluster 7 (*n* = 9)

Discussion {#Sec12}
==========

In this scientometric study, we demonstrated the overall NB research output during the last 38 years, with the total number of publications reaching 12,435 articles in 2018. Overall, the number of NB-related papers has increased 69-fold since the 1980s, probably reflecting the biological and clinical heterogeneity as well as the diversity of NB research sub-fields. We also showed the average annual percentage growth rate of 11.8%. This rate was higher than that for both cancer research as a whole (6.5%) and global pediatric cancer research, (4.3%) indicating high scientific interest in NB research \[[@CR25], [@CR26]\]. We detected an extensive increase in number of publications and corresponding growth rate of NB papers after 1991, which may reflect the concentrated research to establish international criteria for NB diagnosis, staging, and treatment strategies \[[@CR27]--[@CR29]\]. Regarding the number of publications as a proxy for quantity of research, it is difficult to make direct comparisons to other pediatric and non-pediatric oncological scientometric studies, as the time periods of investigation vary significantly and research areas are represented differently in the literature \[[@CR30]\]. For instance, as recently shown by Syrimi et al., pediatric leukemia and tumors of central nervous system were the most dominant research areas during 2007--2016, which may reflect the prevalence of these diseases \[[@CR26]\].

Performance indicators measured by the number of received citations are used to identify the quality of the scientific publication and gauge its impact on the scientific community \[[@CR31]\]. In our study, retrieved documents received a total of 316,017 citations with an average citation per document of 28.35 ± 7.7. This was higher than for other rare oncological diseases, such as male breast cancer with a total number of 76,104 citations \[[@CR32]\], but lower compared to more prevalent cancers, such as female breast cancer (*n* = 4,136,224 citations) \[[@CR33]\].

We showed that 12 (11.6%) of 86 countries were responsible for 80% of NB-related research output. Of these, the USA was the leading country regarding total number of publications, *h*-index, total citations, and average article citations. As a high-income country, the USA allocates a large budget to research and has a vast number of research centers \[[@CR34]--[@CR36]\].

There is a global trend in science towards national and international collaborations to improve patient care \[[@CR37]--[@CR39]\]. Especially for NB as a rare and highly complex oncological disease, international collaboration and the pooling of data is essential for conducting clinical trials of high statistical power. We were able to demonstrate that the USA had the highest collaboration performance, especially with Germany, Italy, and the UK.

Among the top 20 journals publishing articles on NB, 13 (65%) were listed in the category "Oncology" while the remaining 7 (35%) constituted distinct categories such as "Surgery" (*n* = 1), "Neurosciences" (*n* = 3), "Biochemistry Molecular Biology" (*n* = 2), "Multidisciplinary Sciences" (*n* = 1). The frequent publishing of NB-related papers indicates that the interest of readers and journal editors in *Journal of Neurochemistry*, *Journal of Pediatric Surgery*, *PLOS One* and *Neuroscience Letters* was also very high. Moreover, the *Journal of Neurochemistry* published the highest number of NB related articles, indicating the high significance of the molecular, cellular and biochemical aspects of NB research.

The most cited paper was the conference-related paper written by Broder GM, containing modifications to and clarifications of the International Neuroblastoma Staging System (INSS) and International Neuroblastoma Response Criteria (INRC). An additional three out of the ten most-cited articles were directly linked with the molecular and genetic factors involved in NB tumorigenesis. The identification of these tumor features and consequent discovery of druggable targets, such as ganglioside GD2 antibodies, has led to improvement of clinical outcomes \[[@CR40]\]. Another four papers were excellent review/seminar articles focusing predominantly on tumor biology. These reported on the potential for novel targeted treatment options, particularly monoclonal antibodies \[[@CR41]\]. However, among the 465 (9.8%) review articles included in our bibliographic dataset, many excellent papers were not included in the top-ten list. This phenomenon is known as the "Matthew Effect": highly cited papers, scientists, and journals are cited more frequently than those with few citations \[[@CR42]\].

The keywords employed most often by authors reflect the dynamics of research hotspots during the study period. We found that the keywords "neuroblastoma" and "apoptosis" were the most common and showed the greatest increase over time. Additionally, all of the top keywords with the strongest citation burst were related to the molecular-biological topics in NB research, suggesting the high significance of this NB sub-field. However, the examination of the field's conceptual structure through a co-word analysis revealed other thematic network clusters, indicating diversity within research sub-fields.

Some limitations of our study should be addressed in future scientometric research. First, we used only the Web of Science™ database to search for publications, neglecting other search engines such as Scopus, Google Scholar or Index Medicus. Thus, other sources may yield different numbers of research items or citation counts. Second, due to constantly changing citation volumes over time, the results of our study are of temporary nature and valid for the time point of the present study's data extraction (November 12, 2019). Third, the share of non-cited papers should also be considered when determining the *h*-index and impact factor of the author, article, journal and country. Nevertheless, we believe that our study provides a detailed scientometric analysis and improves insights into international research on NB.

Conclusions {#Sec13}
===========

This scientometric study provides an in-depth analysis of global neuroblastoma research, highlighting the multidisciplinary nature of the NB community. Over the past four decades, NB research has progressed enormously, resulting in a better understanding of underlying tumor biology and leading to the development of new molecular therapies. Collaborative research has led to substantial progress in patient stratification and implementation of standardized treatment protocols. Studies like this one are useful for researchers, clinicians, journal editors, and others working on NB in order to understand the strengths and potential gaps in the research and to plan future investments in data collection and science policy. Given the disease burden, especially associated with high-risk NB, a specific analysis of research publications and collaboration networks in this area is warranted to build on the more general scientometric studies.
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**Additional file 1 Figure S1** Individual profiling of the top ten authors with regard to the number of published articles and total citations (TC) received per year. The size of the circles indicate the number of publications per year. **Additional file 2 Figure S2** A choropleth map detailing the geographic distribution of collaborating countries. The color intensity (from light-blue to dark-blue) is proportional to the number of publications. The number of links (presented as red lines) between any two countries represents the strength of collaboration. **Additional file 3 Figure S3** Top 10 keywords with the strongest citation bursts during last 38 years **Additional file 4 Figure S4** Common conceptual frames associated with neuroblastoma studies. Clustering of the 12,435 retrieved articles, including 7 different concepts of clusters of sizes 8, 5, 5, 11, 6, and 2 reflecting concepts frequently linked to neuroblastoma research. **Additional file 5 Figure S5** The three-fields plot shows the relationship between the author's keywords (research contents = right field), references authors use (intellectual roots = left field), and the top authors (middle field). **Additional file 6 Table S1:** Total number of publications with corresponding average citations per item, *h*-index, and annual growth rate **Additional file 7 Table S2:** Citation rate and dynamics
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